Publication | Closed Access

Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial

Relapsing-remitting Multiple SclerosisClinical NeurologyClinical TrialsNeurological ProgressTreatment OptionPharmacotherapyNeurologyMultiple SclerosisMedicine6-Week DosingNatalizumab Versus